HypercholesterolemiaLPACONCT06304415
Elevated Lipoprotein(a) in Hospital Staff
An observational study of Hypercholesterolemia and Lipoprotein Types--Lp System Lp(A) Hyperlipoproteinemia, run by Changi General Hospital at 1 site in Singapore.
Trial summary
The objective of this study is to investigate the prevalence of elevated Lp(a) in the working general population. Read more about this study
- Who is it for?
- Ages 21 to 100 yearsHealthy volunteers can take part
- Conditions the study is for
- Hypercholesterolemia, Lipoprotein Types--Lp System Lp(A) Hyperlipoproteinemia, Cardiovascular Diseases
- How many people
- 2,800 participants
- Where
- 1 siteSingapore
- Study dates
- 1 Apr 2024to 31 Dec 2036
- How long will I take part?
- 10 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 100 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Working general population
Who may be able to join
- Any healthcare workers working in healthcare settings (regardless of PHI and/or private setting) aged 21 and above OR family member such as father, mother, siblings, grandparents, spouse and children aged 12 and above of recruited staff with high Lpa ≥120nmol/l
- Study team members can also be recruited because we are trying to find the prevalence of elevated Lp(a)
Who cannot join
- Inability to provide informed consent.
- Pregnant women.
- Prisoner
Trial locations and contacts
1 site in 1 country.
Singapore1 site
Clinical Trials & Research Unit
Singapore, Singapore, 529889
About this study
Official title: Investigating The Prevalence and Clinical Significance of Elevated Lipoprotein(a) Blood Levels in Hospital Staff
The objective of this study is to investigate the prevalence of elevated Lp(a) in the working general population.
Read the detailed description
The objective of this study is to investigate the prevalence of elevated lipoprotein(a) concentrations and distribution of lipoprotein(a) in a working general population. This is a prospective study investigating the association of lipoprotein(a) with cardiovascular markers and outcomes.
- Conditions
- Hypercholesterolemia, Lipoprotein Types--Lp System Lp(A) Hyperlipoproteinemia, Cardiovascular Diseases
- Medical subject headings
- Hypercholesterolemia, Lipoprotein Types--Lp System Lp(A) Hyperlipoproteinemia, Cardiovascular Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Working General Population | Consenting hospital staff are recruited to this study. Blood test and questionnaires are taken at baseline. Prospective follow-up of cardiovascular events are undertaken. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Distribution and prevalence of elevated Lipoprotein(a)
Investigate the distribution lipoprotein(a) and prevalence of elevated lipoprotein(a) concentrations in various ethnicities.
Measured: 3 years
Secondary outcomes (2)
Correlation of lipoprotein(a) with cardiovascular outcomes
Observational study to assess the correlation of degree of elevation of lipoprotein(a) with cardiovascular outcomes prospectively.
Measured: 10 years
Genetic variants of lipoprotein(a) and cardiovascular outcomes atherosclerotic events
Assess the association of genetic variants of lipoprotein(a) with the measured lipoprotein(a) concentrations in various ethnicities, and prospectively assess the association of these genetic variants with cardiovascular outcomes
Measured: 10 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Mar 2024
- Study start1 Apr 2024
- Primary completion1 Dec 2035 (estimated)
- Study completion31 Dec 2036 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (6)Papers the sponsor has linked to this study.
- Other trials for HypercholesterolemiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 2,800 participants (estimated)
- Target duration
- 10 Years
Sponsor and investigators
- Lead sponsor
- Changi General Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Loh Wann Jia, Changi General Hospital
- Investigators
- Loh Wann Jia, Principal investigator, Singhealth Foundation
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06304415
- Sponsor's protocol ID
- CIRB2023/2651
- Acronym
- LPACO
- Status last verified
- Aug 2025
- First submitted
- 5 Mar 2024
- Last updated
- 18 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Loh WJ, Watts GF. Detection strategies for elevated lipoprotein(a): will implementation let the genie out of the bottle? Curr Opin Endocrinol Diabetes Obes. 2023 Apr 1;30(2):94-102. doi: 10.1097/MED.0000000000000789. Epub 2022 Dec 5.
PubMed 36468313Loh WJ, Chang X, Aw TC, Phua SK, Low AF, Chan MY, Watts GF, Heng CK. Lipoprotein(a) as predictor of coronary artery disease and myocardial infarction in a multi-ethnic Asian population. Atherosclerosis. 2022 May;349:160-165. doi: 10.1016/j.atherosclerosis.2021.11.018. Epub 2021 Nov 26.
PubMed 34887076Loh WJ, Chan DC, Mata P, Watts GF. Familial Hypercholesterolemia and Elevated Lipoprotein(a): Cascade Testing and Other Implications for Contextual Models of Care. Front Genet. 2022 Apr 27;13:905941. doi: 10.3389/fgene.2022.905941. eCollection 2022.
PubMed 35571022Nestel P, Loh WJ, Ward NC, Watts GF. New Horizons: Revival of Lipoprotein (a) as a Risk Factor for Cardiovascular Disease. J Clin Endocrinol Metab. 2022 Nov 23;107(11):e4281-e4294. doi: 10.1210/clinem/dgac541.
PubMed 36108076Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, Dweck MR, Koschinsky M, Lambert G, Mach F, McNeal CJ, Moriarty PM, Natarajan P, Nordestgaard BG, Parhofer KG, Virani SS, von Eckardstein A, Watts GF, Stock JK, Ray KK, Tokgozoglu LS, Catapano AL. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022 Oct 14;43(39):3925-3946. doi: 10.1093/eurheartj/ehac361.
PubMed 36036785Loh WJ, Tun MH, Shak B, Phua SK, Lim G, Yap C, Khoo J, Puar T, Heng CK, Foo R, Watts GF, Dalan R, Aw TC. Lipoprotein(a), apolipoprotein B and other lipid biomarkers in Asian healthcare workers. Lipids Health Dis. 2026 Mar 6;25(1):88. doi: 10.1186/s12944-026-02912-7.
PubMed 41792760
Study at a glance
From the registry record, last updated by the sponsor on 18 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Investigating The Prevalence and Clinical Significance of Elevated Lipoprotein(a) Blood Levels in Hospital Staff
- ClinicalTrials.gov ID
- NCT06304415
- Acronym / sponsor ID
- LPACO / CIRB2023/2651
- Conditions
- Hypercholesterolemia, Lipoprotein Types--Lp System Lp(A) Hyperlipoproteinemia, Cardiovascular Diseases
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 2,800 participants (estimated)
- Lead sponsor
- Changi General HospitalUniversity, hospital or other
- Study start
- 1 Apr 2024 (actual)
- Primary completion
- 1 Dec 2035 (estimated)
- Study completion
- 31 Dec 2036 (estimated)
- First posted
- 12 Mar 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of this study is to investigate the prevalence of elevated Lp(a) in the working general population.
Detailed description
The objective of this study is to investigate the prevalence of elevated lipoprotein(a) concentrations and distribution of lipoprotein(a) in a working general population. This is a prospective study investigating the association of lipoprotein(a) with cardiovascular markers and outcomes.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 10 Years
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Working General Population | – | –Consenting hospital staff are recruited to this study. Blood test and questionnaires are taken at baseline. Prospective follow-up of cardiovascular events are undertaken. |
Who may qualify
- Ages
- 21 to 100 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Working general population
Key inclusion criteria (2 listed)
- Any healthcare workers working in healthcare settings (regardless of PHI and/or private setting) aged 21 and above OR family member such as father, mother, siblings, grandparents, spouse and children aged 12 and above of recruited staff with high Lpa ≥120nmol/l
- Study team members can also be recruited because we are trying to find the prevalence of elevated Lp(a)
Key exclusion criteria (3 listed)
- Inability to provide informed consent.
- Pregnant women.
- Prisoner
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Distribution and prevalence of elevated Lipoprotein(a)
Time frame: 3 years
Investigate the distribution lipoprotein(a) and prevalence of elevated lipoprotein(a) concentrations in various ethnicities.
2 secondary outcomes
Correlation of lipoprotein(a) with cardiovascular outcomes
Time frame: 10 years
Genetic variants of lipoprotein(a) and cardiovascular outcomes atherosclerotic events
Time frame: 10 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Mar 2026.
- Background: PubMed 36468313Loh WJ, Watts GF. Detection strategies for elevated lipoprotein(a): will implementation let the genie out of the bottle? Curr Opin Endocrinol Diabetes Obes. 2023 Apr 1;30(2):94-102. doi: 10.1097/MED.0000000000000789. Epub 2022 Dec 5.
- Background: PubMed 34887076Loh WJ, Chang X, Aw TC, Phua SK, Low AF, Chan MY, Watts GF, Heng CK. Lipoprotein(a) as predictor of coronary artery disease and myocardial infarction in a multi-ethnic Asian population. Atherosclerosis. 2022 May;349:160-165. doi: 10.1016/j.atherosclerosis.2021.11.018. Epub 2021 Nov 26.
- Background: PubMed 35571022Loh WJ, Chan DC, Mata P, Watts GF. Familial Hypercholesterolemia and Elevated Lipoprotein(a): Cascade Testing and Other Implications for Contextual Models of Care. Front Genet. 2022 Apr 27;13:905941. doi: 10.3389/fgene.2022.905941. eCollection 2022.
- Background: PubMed 36108076Nestel P, Loh WJ, Ward NC, Watts GF. New Horizons: Revival of Lipoprotein (a) as a Risk Factor for Cardiovascular Disease. J Clin Endocrinol Metab. 2022 Nov 23;107(11):e4281-e4294. doi: 10.1210/clinem/dgac541.
- Background: PubMed 36036785Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, Dweck MR, Koschinsky M, Lambert G, Mach F, McNeal CJ, Moriarty PM, Natarajan P, Nordestgaard BG, Parhofer KG, Virani SS, von Eckardstein A, Watts GF, Stock JK, Ray KK, Tokgozoglu LS, Catapano AL. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022 Oct 14;43(39):3925-3946. doi: 10.1093/eurheartj/ehac361.
- Derived from this study: PubMed 41792760Loh WJ, Tun MH, Shak B, Phua SK, Lim G, Yap C, Khoo J, Puar T, Heng CK, Foo R, Watts GF, Dalan R, Aw TC. Lipoprotein(a), apolipoprotein B and other lipid biomarkers in Asian healthcare workers. Lipids Health Dis. 2026 Mar 6;25(1):88. doi: 10.1186/s12944-026-02912-7.
- Individual participant dataSharing planned: No
Related trials for Hypercholesterolemia
Not yet recruitingPhase 1/2
EDIT-401 in Adults Who Require Additional Lowering of Low-Density Lipoprotein Cholesterol (LDL-C)
Heterozygous Familial Hypercholesterolemia (HeFH)
RecruitingObservational study
Causes and Natural History of Dyslipidemias
Hypercholesterolemia, Atherosclerosis
RecruitingPhase 3
Study of Zodasiran in Adolescent Participants With Homozygous Familial Hypercholesterolemia
Homozygous Familial Hypercholesterolemia
RecruitingPhase 4
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
Percutaneous Coronary Intervention, Peripheral Endovascular Intervention
RecruitingPhase 1
Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia
Hypercholesterolemia, Hypertriglyceridemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Loh Wann Jia principal investigator
Singhealth Foundation
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hypercholesterolemia and Lipoprotein Types--Lp System Lp(A) Hyperlipoproteinemia, run by Changi General Hospital at 1 site in Singapore.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 18 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Singapore. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Distribution and prevalence of elevated Lipoprotein(a) (time frame: 3 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06304415, which also lists 6 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Mar 2026.